Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is N/A as of Tuesday, October 6, 2026.
GROSS MARGIN
N/A
Market Cap
$3.50M
Gross Margin
79.65%
TTM Avg
78.98%
3Y Avg
76.82%
5Y Avg
80.07%
Market Cap
$3.30M
Gross Margin
36.10%
TTM Avg
40.19%
3Y Avg
41.87%
5Y Avg
47.28%
Market Cap
$3.32M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
50.00%
Market Cap
$3.25M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eocene Ltd. (EOCN) | $3.52M | N/A | N/A | N/A | N/A |
| Nexalin Technology, Inc. (NXL)vs › | $3.50M | 79.65% | 78.98% | 76.82% | 80.07% |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | 0.00% | 0.00% | 0.00% | 0.00% |
| Moolec Science S.A. (MLEC)vs › | $3.46M | 34.17% | 21.29% | 6.69% | 5.35% |
| Evogene Ltd. (EVGN)vs › | $3.40M | -6.25% | 25.54% | 36.71% | 34.86% |
| IceCure Medical Ltd (ICCM)vs › | $3.30M | 36.10% | 40.19% | 41.87% | 47.28% |
| Aethlon Medical, Inc. (AEMD)vs › | $3.32M | 0.00% | 0.00% | 25.00% | 50.00% |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.25M | 0.00% | 0.00% | 0.00% | 0.00% |
| MBody AI Ltd. (MBAI)vs › | $3.17M | 0.00% | 0.00% | 0.00% | 0.00% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.97M | 0.00% | 41.76% | -40.89% | -27.26% |
Gross Margin
N/A
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
